Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study

Meera Agar, Timothy To, John Plummer, Amy Abernethy, David Currow

    Research output: Contribution to journalArticlepeer-review

    11 Citations (Scopus)

    Abstract

    Introduction: Anti-cholinergic medications have been associated with increased risks of cognitive impairment, premature mortality and increased risk of hospitalisation. Anti-cholinergic load associated with medication increases as death approaches in those with advanced cancer, yet little is known about associated adverse outcomes in this setting. Methods: A substudy of 112 participants in a randomised control trial who had cancer and an Australia modified Karnofsky Performance Scale (AKPS) score (AKPS) of 60 or above, explored survival and health service utilisation; with anti-cholinergic load calculated using the Clinician Rated Anti-cholinergic Scale (modified version) longitudinally to death. A standardised starting point for prospectively calculating survival was an AKPS of 60 or above. Results: Baseline entry to the sub-study was a mean 62±81 days (median 37, range 1-588) days before death (survival), with mean of 4.8 (median 3, SD 4.18, range 1 - 24) study assessments in this time period. Participants spent 22% of time as an inpatient. There was no significant association between anti-cholinergic score and time spent as an inpatient (adjusted for survival time) (p=0.94); or survival time. Discussion: No association between anti-cholinergic load and survival or time spent as an inpatient was seen. Future studies need to include cognitively impaired populations where the risks of symptomatic deterioration may be more substantial.

    Original languageEnglish
    Pages (from-to)745-752
    Number of pages8
    JournalJournal of Palliative Medicine
    Volume13
    Issue number6
    DOIs
    Publication statusPublished - 1 Jun 2010

    Fingerprint Dive into the research topics of 'Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study'. Together they form a unique fingerprint.

    Cite this